Initiation of intensive insulin therapy has been suggested for stroke patients, but currently available data fail to identify the clinical benefits of the therapy, for example, the UK Glucose Insulin in Stroke Trial (GIST‐UK) showed no significant clinical benefit associated with insulin therapy in 933 patients with stroke (Gray et al., 2007). The gene discussed is INS; the disease is stroke disorder.